Tag Archives: Lexicon Pharmaceuticals

March, 2017

  • 1 March

    FDA Approves Lexicon’s Xermelo for Carcinoid Syndrome Diarrhea

    The Woodlands, Texas, February 28, 2017 – Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the U.S. Food and Drug Administration (FDA) has approved XERMELO™ (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) …